Last reviewed · How we verify

PCA Ketamine

Universidad de Antioquia · FDA-approved active Small molecule

PCA Ketamine is a patient-controlled anesthesia formulation of ketamine that acts as an NMDA receptor antagonist to produce dissociative anesthesia and analgesia.

PCA Ketamine is a patient-controlled anesthesia formulation of ketamine that acts as an NMDA receptor antagonist to produce dissociative anesthesia and analgesia. Used for Anesthesia induction and maintenance, Acute pain management in perioperative settings.

At a glance

Generic namePCA Ketamine
Also known asKetamine PCA
SponsorUniversidad de Antioquia
Drug classNMDA receptor antagonist
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ketamine blocks N-methyl-D-aspartate (NMDA) receptors on glutamatergic neurons, interrupting pain signal transmission and producing rapid-onset dissociative anesthesia. The PCA (patient-controlled anesthesia) delivery system allows patients to self-administer doses within programmed safety limits, providing on-demand analgesia and sedation. This formulation is used in clinical settings where patient-controlled dosing of ketamine's anesthetic and analgesic properties is therapeutically beneficial.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: